New Zealand markets closed

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
38.01+2.44 (+6.87%)
As of 11:53AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 373.24M
Enterprise value 373.22M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.49k
Enterprise value/revenue N/A
Enterprise value/EBITDA -8.40

Trading information

Stock price history

Beta (5Y monthly) 2.43
52-week change 3302.83%
S&P500 52-week change 329.57%
52-week high 349.87
52-week low 33.03
50-day moving average 328.02
200-day moving average 311.76

Share statistics

Avg vol (3-month) 3945.38k
Avg vol (10-day) 3293.18k
Shares outstanding 510.49M
Implied shares outstanding 610.49M
Float 86.77M
% held by insiders 10.68%
% held by institutions 156.68%
Shares short (15 Mar 2024) 4403.79k
Short ratio (15 Mar 2024) 41.02
Short % of float (15 Mar 2024) 44.49%
Short % of shares outstanding (15 Mar 2024) 43.85%
Shares short (prior month 15 Feb 2024) 492.9k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 314 Feb 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-59.57%
Return on equity (ttm)-341.98%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -44.44M
Net income avi to common (ttm)-44.6M
Diluted EPS (ttm)-10.31
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)20.91M
Total cash per share (mrq)1.99
Total debt (mrq)20.88M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.74
Book value per share (mrq)-1.56

Cash flow statement

Operating cash flow (ttm)-36.1M
Levered free cash flow (ttm)-21.24M